International Aids Vaccine Initiative

Contrafect Corporation

Cornell University

The Scripps Research Institute

Simon Hoffenberg

Christopher Lee Parks

Michael Wittekind

Raymond Schuch

Ivo Lorenz

Maoli Yuan

Aaron J Wilson

Xinsheng Zhang

Kevin Wright

Christy Jurgens

Arban Domi

Maria J Chiuchiolo

Svetlana Rabinovich

John S Moore

Sanjay K Phogat

Wayne C Koff

C Richter King

Ian A Wilson

Andre Marozsan

Andrew B Ward

Charles Richter King

Rogier W Sanders

Michael P Caulfield

Albert Cupo

Rogier Sanders

Hansi Dean

P J Klasse

Jean-Philippe Julien

Alexei Carpov

Denise Wagner

Christy K Jurgens

Chris Parks

Ivo C Lorenz

Per Johan Klasse

Michael Caulfield

Jean-Phillippe Julien

John Moore

Kevin J Wright

The present disclosure provides methods and compositions useful for the prophylactic and therapeutic amelioration and treatment of infections caused by Gram-negative bacteria, including. The disclosure further provides compositions and methods of incorporating and utilizing lysin polypeptides of the present disclosure for augmenting the efficacy of antibiotics generally suitable for the treatment of Gram-negative bacterial infection.

Lysin polypeptides active against Gram-negative bacteria

The present invention relates to methods of developing gene inserts that are more compatible with the host vectors by modifying a protein sequence to lessen potential interference with vector propagation while ensuring that the protein is expressed and processed efficiently and maintains desired structural features, and designing a gene with a nucleotide sequence that resembles the base composition of the host vector genome.

Methods to improve vector expression and genetic stability

The present application relates to novel HIV-1 envelope glycoproteins, which may be utilized as HIV-1 vaccine immunogens, and antigens for crystallization, electron microscopy and other biophysical, biochemical and immunological studies for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions, which are formulated into the vaccines of the present invention.

HIV-1 envelope glycoprotein

The present application relates to novel HIV-1 envelope glycoproteins which may be utilized as an HIV-1 vaccine immunogens, antigens for crystallization and for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.

Methods for identifying broadly neutralizing antibodies utilizing recombinant HIV-1 envelope glycoproteins comprising stabilizing mutations

The present application relates to a novel HIV-1 envelope glycoprotein which may be utilized as an HIV-1 vaccine immunogen, antigens for crystallization and for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.

Growing community of inventors

Hartsdale, NY, United States of America

Simon Hoffenberg